InvestorsHub Logo
Followers 37
Posts 6856
Boards Moderated 1
Alias Born 09/06/2014

Re: Jumpinjackas post# 39734

Saturday, 09/10/2016 5:24:39 PM

Saturday, September 10, 2016 5:24:39 PM

Post# of 45295
Manuso says he is "[looking] forward to discussing preliminary, top-line results of the Company’s recently concluded Phase 2A clinical trial testing the impact of the Company’s proprietary oral ampakine, CX-1739, on opioid-induced respiratory depression" at Rodman and Redshaw on Monday the 12th?

http://respirerx.com/respirerx-pharmaceuticals-inc-to-present-at-the-rodman-renshaw-18th-annual-global-investment-conference-on-september-12-2016/

The dronabinol results are pushed back to Q4. That's not Manuso's fault, and that does not, in my mind, indicate a failure to meet endpoints.

I think we ALL expected the dronabinol news before the R/S, including Manuso, but I think Manuso wanted the attractive share structure and PPS when he presents at Rodman & Redshaw. We'll find out Monday/Tuesday whether the R/S coming first was a smart move by Manuso.


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RSPI News